BioPorto Submits Pediatric Application to FDA for The NGAL Test™ Under Breakthrough Designation

World News: . []

BioPorto AS BioPorto LINK  today that the company has submitted an application to the US Food and Drug Administration FDA for regulatory LINK  of The NGAL Test in the US for risk assessment of acute kidney injury AKI”)...

More news and information about BioPorto A/S

Published By:

Globe Newswire: 12:57 GMT Wednesday 15th May 2019

Published: .

Search for other references to "bioporto" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us